Skip to content
ZNTL·Nasdaq·US

Zentalis

Zentalis is a clinical-stage biopharmaceutical company focused on developing small-molecule oncology therapies, led by the WEE1 inhibitor azenosertib. Its pipeline is centered on biomarker-driven treatment approaches for ovarian cancer and other tumor types, with late-stage clinical development and commercial preparedness activities underway.

Recent Activity

Updated Oct 24, 2026
–Zentalis Pharmaceuticals announced the first overall survival data for azenosertib from DENALI Part 1b, published in an ESMO Congress 2026 abstract.
–Azenosertib monotherapy produced a median overall survival of 15.8 months in patients with Cyclin E1-positive platinum-resistant ovarian cancer.

Past updates are part of the Pro plan.

Thematic Position

ZNTL

Relationship Groups

Suppliers1
Partners2
Licensing1
Competitors7

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

12 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

government licensing rightsdomestic manufacturing requirementmarch-in rights
US government march-in rights and domestic manufacturing preference under Bayh-Dole Act
SEC 10-QAug 6, 2026

The full regulatory passage is part of the Pro plan.

12 more · Regulatory and geopolitical insights are part of the Pro plan.